Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Faces More Probes On Generic Price Hikes in UK

Executive Summary

As Concordia finds itself in the dock again, this time over its pricing of the essential thyroid treatment liothyronine, the UK's Competition and Markets Authority has recently opened four new investigations into "suspected abuse of dominance" concerning generics.

You may also be interested in...



UK's Crackdown On Anti-Competitive Deals Continues; Actavis In Firing Line Again

The UK's competition authority is keen to expose supposed pay-for-delay deals made by pharmaceutical firms, and is warning drug suppliers to think twice before attempting agreements that slow the entry of generic products onto the UK market.

UK Fine For Pfizer/Flynn’s ‘Excessive And Unfair’ Pricing Sends Clear Message To Others

The UK competition authority has fined Pfizer and Flynn Pharma a total of £90m for charging “excessive and unfair” prices for phenytoin sodium capsules; Pfizer has said it will appeal. With an earlier CMA decision to impose a hefty fine on GlaxoSmithKline for its part in a pay-for-delay deal, companies should pay careful consideration to any competition issues raised by their pricing strategies for marketed drugs.

GSK Gets Stung By First UK Pay-For-Delay Ruling

Competition and Markets authority levies fines on GSK and two generics firms for agreement on paroxetine.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel